MSD Korea launches V65 campaign for Vioxx in Korea

Published: 2003-10-20 06:57:00

Updated: 2003-10-20 06:57:00

MSD Korea said it has initiated a V65 campaign towards local doctors and patients from last September as part of its efforts to promote is lead product Vioxx for the treatment of arthritis, adding that its earlier "Vonmax Club" campaign, which has launched last May, is gaining good reputation fro...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK